These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 12815565

  • 1. Effect of Valsartan on hospitalization: results from Val-HeFT.
    Carson P, Tognoni G, Cohn JN.
    J Card Fail; 2003 Jun; 9(3):164-71. PubMed ID: 12815565
    [Abstract] [Full Text] [Related]

  • 2. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN.
    Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651
    [Abstract] [Full Text] [Related]

  • 3. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Reed SD, Friedman JY, Velazquez EJ, Gnanasakthy A, Califf RM, Schulman KA.
    Am Heart J; 2004 Jul 20; 148(1):122-8. PubMed ID: 15215801
    [Abstract] [Full Text] [Related]

  • 4. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators.
    N Engl J Med; 2001 Dec 06; 345(23):1667-75. PubMed ID: 11759645
    [Abstract] [Full Text] [Related]

  • 5. Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT).
    Baruch L, Glazer RD, Aknay N, Vanhaecke J, Heywood JT, Anand I, Krum H, Hester A, Cohn JN.
    Am Heart J; 2004 Dec 06; 148(6):951-7. PubMed ID: 15632877
    [Abstract] [Full Text] [Related]

  • 6. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS, Rector TS, Kuskowski M, Thomas S, Holwerda NJ, Cohn JN.
    Circ Heart Fail; 2008 May 06; 1(1):34-42. PubMed ID: 19808268
    [Abstract] [Full Text] [Related]

  • 7. Interaction between baseline and early worsening of renal function and efficacy of renin-angiotensin-aldosterone system blockade in patients with heart failure: insights from the Val-HeFT study.
    Lesogor A, Cohn JN, Latini R, Tognoni G, Krum H, Massie B, Zalewski A, Kandra A, Hua TA, Gimpelewicz C.
    Eur J Heart Fail; 2013 Nov 06; 15(11):1236-44. PubMed ID: 23787721
    [Abstract] [Full Text] [Related]

  • 8. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R, Valsartan Heart Failure Trial Investigators.
    Circulation; 2003 Sep 16; 108(11):1306-9. PubMed ID: 12939207
    [Abstract] [Full Text] [Related]

  • 9. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis.
    Smith DG, Cerulli A, Frech FH.
    Clin Ther; 2005 Jun 16; 27(6):951-9. PubMed ID: 16117995
    [Abstract] [Full Text] [Related]

  • 10. Digoxin use and heart failure outcomes: results from the Valsartan Heart Failure Trial (Val-HeFT).
    Butler J, Anand IS, Kuskowski MA, Rector T, Carson P, Cohn JN, Val-HeFT Investigators.
    Congest Heart Fail; 2010 Jun 16; 16(5):191-5. PubMed ID: 20887614
    [Abstract] [Full Text] [Related]

  • 11. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT.
    Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN.
    Eur J Heart Fail; 2013 May 16; 15(5):511-8. PubMed ID: 23291728
    [Abstract] [Full Text] [Related]

  • 12. The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
    Pradelli L, Iannazzo S, Zaniolo O.
    Am J Cardiovasc Drugs; 2009 May 16; 9(6):383-92. PubMed ID: 19929036
    [Abstract] [Full Text] [Related]

  • 13. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 16; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 14. Elevated plasma renin activity predicts adverse outcome in chronic heart failure, independently of pharmacologic therapy: data from the Valsartan Heart Failure Trial (Val-HeFT).
    Masson S, Solomon S, Angelici L, Latini R, Anand IS, Prescott M, Maggioni AP, Tognoni G, Cohn JN, Val-Heft Investigators.
    J Card Fail; 2010 Dec 16; 16(12):964-70. PubMed ID: 21111986
    [Abstract] [Full Text] [Related]

  • 15. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.
    Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, Chiang YT, Cohn JN.
    Eur J Heart Fail; 2004 Dec 16; 6(7):937-45. PubMed ID: 15556056
    [Abstract] [Full Text] [Related]

  • 16. Valsartan for the treatment of heart failure.
    Latini R, Masson S, Staszewsky L, Maggioni AP.
    Expert Opin Pharmacother; 2004 Jan 16; 5(1):181-93. PubMed ID: 14680446
    [Abstract] [Full Text] [Related]

  • 17. Valsartan in chronic heart failure.
    Campbell DJ.
    N Engl J Med; 2002 Apr 11; 346(15):1173-4. PubMed ID: 11951863
    [No Abstract] [Full Text] [Related]

  • 18. The benefits of valsartan in the treatment of heart failure: results from Val-HeFT.
    Tan LB, Schlosshan D, Williams SG.
    Int J Clin Pract; 2004 Feb 11; 58(2):184-91. PubMed ID: 15055867
    [Abstract] [Full Text] [Related]

  • 19. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
    Vachiéry JL.
    Rev Med Brux; 2003 Sep 11; 24(4):A249-52. PubMed ID: 14606288
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May 11; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.